» Articles » PMID: 34853791

Establishment and Validation of an MTORC1 Signaling-Related Gene Signature to Predict Overall Survival in Patients with Hepatocellular Carcinoma

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2021 Dec 2
PMID 34853791
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Accurate and effective biomarkers for the prognosis of patients with hepatocellular carcinoma (HCC) are poorly identified. A network-based gene signature may serve as a valuable biomarker to improve the accuracy of risk discrimination in patients.

Methods: The expression levels of cancer hallmarks were determined by Cox regression analysis. Various bioinformatic methods, such as GSEA, WGCNA, and LASSO, and statistical approaches were applied to generate an MTORC1 signaling-related gene signature (MSRS). Moreover, a decision tree and nomogram were constructed to aid in the quantification of risk levels for each HCC patient.

Results: Active MTORC1 signaling was found to be the most vital predictor of overall survival in HCC patients in the training cohort. MSRS was established and proved to hold the capacity to stratify HCC patients with poor outcomes in two validated datasets. Analysis of the patient MSRS levels and patient survival data suggested that the MSRS can be a valuable risk factor in two validated datasets and the integrated cohort. Finally, we constructed a decision tree which allowed to distinguish subclasses of patients at high risk and a nomogram which could accurately predict the survival of individuals.

Conclusions: The present study may contribute to the improvement of current prognostic systems for patients with HCC.

Citing Articles

Retracted: Establishment and Validation of an MTORC1 Signaling-Related Gene Signature to Predict Overall Survival in Patients with Hepatocellular Carcinoma.

International B Biomed Res Int. 2024; 2024:9851737.

PMID: 38549990 PMC: 10977186. DOI: 10.1155/2024/9851737.


Comprehensive analysis of the clinical significance, immune infiltration, and biological role of MARCH ligases in HCC.

Cao J, Tu D, Zhou J, Jiang G, Jin S, Su B Front Immunol. 2022; 13:997265.

PMID: 36263042 PMC: 9573977. DOI: 10.3389/fimmu.2022.997265.

References
1.
Sun C, Chang Y, Pan C . Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 2011; 58(7):1054-63. DOI: 10.1111/j.1365-2559.2011.03856.x. View

2.
Ferrin G, Guerrero M, Amado V, Rodriguez-Peralvarez M, Mata M . Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci. 2020; 21(4). PMC: 7072933. DOI: 10.3390/ijms21041266. View

3.
Bueno L, De Alwis D, Pitou C, Yingling J, Lahn M, Glatt S . Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2007; 44(1):142-50. DOI: 10.1016/j.ejca.2007.10.008. View

4.
Tolba R, Kraus T, Liedtke C, Schwarz M, Weiskirchen R . Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab Anim. 2015; 49(1 Suppl):59-69. DOI: 10.1177/0023677215570086. View

5.
Mootha V, Lindgren C, Eriksson K, Subramanian A, Sihag S, Lehar J . PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267-73. DOI: 10.1038/ng1180. View